GFPT2 and synucleinopathy: For synucleinopathies, future work aimed at increasing the enzymatic activity of GFPT2, or enhancing flux downstream in the pathway with GlcNAc or potent derivatives, may provide a new class of lysosomal enhancers to combat protein aggregation.